Recombinant human erythropoietin in neonates: Guidelines for clinical practice from the French Society of Neonatology;L'érythropoïétine humaine recombinante chez le nouveau-né: Recommandations pour la pratique clinique de la Société française de néonatologie

Archives de Pediatrie

Volumn 22, Issue 10, 2015, Pages 1092-1097

  Lopez, E ^a   Beuchee A ^b   Truffert, P ^c   Pouvreau, N ^d   Patkai, J ^e   Baud, O ^f   Boubred, F ^g   Flamant, C ^h   Jarreau, P H ^e  

^a Centre de Pediatrie Clocheville   (France)

^b SERVICE DE RHUMATOLOGIE   (France)

^c LILLE UNIVERSITY HOSPITAL   (France)

^d BORDEAUX UNIVERSITY HOSPITAL   (France)

^e ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^f HÔPITAL ROBERT DEBRÉ   (France)

^g HÔPITAL DE LA CONCEPTION   (France)

^h NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ERYTHROPOIETIN; ERYTHROPOIETIN; RECOMBINANT PROTEIN;

ARTICLE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FRANCE; HUMAN; LOW DRUG DOSE; LUNG DYSPLASIA; NECROTIZING ENTEROCOLITIS; NEUROPROTECTION; PRACTICE GUIDELINE; PREMATURITY; RETROLENTAL FIBROPLASIA; RISK REDUCTION; ANEMIA, NEONATAL; BLOOD; NEWBORN; UTILIZATION;

ANEMIA, NEONATAL; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; RECOMBINANT PROTEINS;

EID: 84942551221     PISSN: 0929693X     EISSN: 1769664X     Source Type: Journal    
DOI: 10.1016/j.arcped.2015.07.001     Document Type: Article

References (32)

1. Kirpalani H., Whyte R.K., Andersen C., et al. The premature infants in need of transfusion (PINT) study: a randomized, controlled trial of a restrictive (low) versus liberal (high) transfusion threshold for extremely low birth weight infants. J Pediatr 2006, 149:301-307.
2. Bishara N., Ohls R.K. Current controversies in the management of the anemia of prematurity. Semin Perinatol 2009, 33:29-34.
3. Pillonel J., Laperche S. Trends in risk of transfusion-transmitted viral infections (HIV, HCV, HBV) in France between 1992 and 2003 and impact of nucleic acid testing (NAT). Euro Surveill 2005, 10:5-8.
4. Valieva O.A., Strandjord T.P., Mayock D.E., et al. Effects of transfusions in extremely low birth weight infants: a retrospective study. J Pediatr 2009, 155:331-370.
5. Blau J., Calo J.M., Dozor D., et al. Transfusion-related acute gut injury: necrotizing enterocolitis in very low birth weight neonates after packed red blood cell transfusion. J Pediatr 2011, 158:403-409.
6. Paul D.A., Mackley A., Novitsky A., et al. Increased odds of necrotizing enterocolitis after transfusion of red blood cells in premature infants. Pediatrics 2011, 127:635-641.
7. dos Santos A.M., Guinsburg R., de Almeida M.F., et al. Red blood cell transfusions are independently associated with intra-hospital mortality in very low birth weight preterm infants. J Pediatr 2011, 159:371-460.
8. Rabe H., Diaz-Rossello J.L., Duley L., et al. Effect of timing of umbilical cord clamping and other strategies to influence placental transfusion at preterm birth on maternal and infant outcomes. Cochrane Database Syst Rev 2012, 8:CD003248.
9. Rao R., Georgieff M.K. Iron therapy for preterm infants. Clin Perinatol 2009, 36:27-42.
10. Aher S.M., Ohlsson A. Late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014, 4:CD004868.
11. Ohlsson A., Aher S.M. Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2014, 4:CD004863.
12. Aher S.M., Ohlsson A. Early versus late erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 2012, 10:CD004865.
13. Maier R.F., Obladen M., Kattner E., et al. High-versus low-dose erythropoietin in extremely low birth weight infants. The European Multicenter rhEPO Study Group. J Pediatr 1998, 132:866-870.
14. Ohls R.K., Veerman M.W., Christensen R.D. Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J Pediatr 1996, 128:518-523.
15. Costa S., Romagnoli C., Zuppa A.A., et al. How to administrate erythropoietin, intravenous or subcutaneous?. Acta Paediatr 2013, 102:579-583.
16. Fauchere J.C., Dame C., Vonthein R., et al. An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics 2008, 122:375-382.
17. Juul S.E., McPherson R.J., Bauer L.A., et al. A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: pharmacokinetics and safety. Pediatrics 2008, 122:383-391.
18. Romagnoli C., Zecca E., Gallini F., et al. Do recombinant human erythropoietin and iron supplementation increase the risk of retinopathy of prematurity?. Eur J Pediatr 2000, 159:627-628.
19. Brown M.S., et al. Association between higher cumulative doses of recombinant erythropoietin and risk for retinopathy of prematurity. J Aapos 2006, 10:143-149.
20. Suk K.K., Barón A.E., France E.K., et al. Human recombinant erythropoietin and the incidence of retinopathy of prematurity: a multiple regression model. J AAPOS 2008, 12:233-238.
21. Xu X.J., Huang H.Y., Chen H.L. Erythropoietin and retinopathy of prematurity: a meta-analysis. Eur J Pediatr 2014, 173:1355-1364.
22. Newton N.R., Leonard C.H., Piecuch R.E., et al. Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. J Perinatol 1999, 19:403-406.
23. Ohls R.K., Ehrenkranz R.A., Das A., et al. Neurodevelopmental outcome and growth at 18 to 22 months' corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics 2004, 114:1287-1291.
24. Bierer R., Peceny M.C., Hartenberger C.H., et al. Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics 2006, 118:e635-e640.
25. Brown M.S., Eichorst D., Lala-Black B., et al. Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants. Pediatrics 2009, 124:e681-e687.
26. Neubauer A.P., Voss W., Wachtendorf M., et al. Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Ann Neurol 2010, 67:657-666.
27. Leuchter R.H., Gui L., Poncet A., et al. Association between early administration of high-dose erythropoietin in preterm infants and brain MRI abnormality at term-equivalent age. JAMA 2014, 312:817-824.
28. Elmahdy H., El-Mashad A.R., El-Bahrawy H., et al. Human recombinant erythropoietin in asphyxia neonatorum: pilot trial. Pediatrics 2010, 125:e1135-e1142.
29. Zhu C., Kang W., Xu F., et al. Erythropoietin improved neurologic outcomes in newborns with hypoxic-ischemic encephalopathy. Pediatrics 2009, 124:e218-e226.
30. Wu Y.W., Bauer L.A., Ballard R.A., et al. Erythropoietin for neuroprotection in neonatal encephalopathy: safety and pharmacokinetics. Pediatrics 2012, 130:683-691.
31. Patkai J. Efficacy of erythropoietin to improve survival and neurological outcome in hypoxic ischemic encephalopathy (Neurepo). ClinicalTrials.gov 2014, [NCT01732146]. https://clinicaltrials.gov/ct2/show/NCT01732146.
32. Benders M.J., van der Aa N.E., Roks M., et al. Feasibility and safety of erythropoietin for neuroprotection after perinatal arterial ischemic stroke. J Pediatr 2014, 164:481-560.